Johnson & Johnson denied quick win in CareFirst's US antitrust case over Stelara
MLex Summary: Johnson & Johnson and Janssen Biotech were denied a summary judgment against CareFirst’s claims of antitrust injury over J&J’s efforts to delay the introduction of biosimilar competition for the...To view the full article, register now.
Already a subscriber? Click here to view full article